Navigation Links
Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
Date:4/26/2010

PRINCETON, N.J., April 26 /PRNewswire/ -- Ophthotech Corp. ("Ophthotech"), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).  

The Phase II trial will assess the efficacy and safety of the combination treatment regimen with approximately 444 patients enrolled at sites in the U.S., Europe and Latin America. In a Phase I clinical study, 59 percent of patients treated with E10030 and Lucentis, an anti-VEGF agent, gained significant vision (3-line gain or better) 12 weeks after the start of therapy.  Notably, there was a mean decrease of 86% in the area of choroidal neovascularization (CNV) at 12 weeks.  In comparison, current standard of care utilizing monotherapy anti-VEGF treatment does not induce significant neovascular regression and results in 3-line or better visual gain in approximately one third of patients.

"With current standard of care, the majority of wet AMD patients do not achieve significant visual gain nor neovascular regression," said Samir Patel, MD, president and CEO of Ophthotech. "Combination therapy with E10030 demonstrates a significant advancement in the treatment of wet AMD.  The magnitude of neovascular regression noted in this Phase 1 study appears to be associated with a significant visual gain in the majority of these patients after only 12 weeks, a result not seen with anti-VEGF treatment alone."

Wet AMD is characterized by the
'/>"/>

SOURCE Ophthotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
4. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
5. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
6. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
7. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
8. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
9. S.C. Medical Home Pilot for Diabetes Enrolls 1,110
10. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... More than 3,500 attendees from top pharmaceutical, fine chemical ... conference, which includes on-site education sessions, daily networking events ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ... need for oxygen when air is thin," states Dr Barnes. She ...
(Date:1/14/2014)... WASHINGTON, New York , January 14, ... http://www.equashield.com ), the leading provider of Closed System Transfer Devices (CSTD) ... has achieved 60% year-over-year sales growth for ... Equashield,s closed systems reduce the risk of ... other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... IPSWICH, Mass., April 12, 2011 New England Biolabs ... of reagents for life science research, announces that it ... the Netherlands, and Imperial Life Sciences (ILS), based in ... BIOKE, a Cell Signaling Technology (CST) Europe ...
... leading EchoStim® Echogenic Insulated needle has been improved. ... Blocks (PNBs) using nerve stimulation and ultrasound guidance ... has more, brighter, easier to see reflectors, which ... the benefits of using both nerve block techniques ...
Cached Medicine Technology:New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... it may have prevented, treated eye infections , SATURDAY, ... worn thousands of years ago by Queen Nefertiti and ... enhance beauty alone: New research suggests that the ancient ... , Some ancient Egyptians thought their lead-based black ...
... ... its’ addition of three exceptional leaders to their management team. Anne Reynolds and ... aboard as the Client Accounting Manager. , ... Columbus, OH (PRWEB) January 22, 2010 -- ADVOCATE, the premier ...
... ... Parkinson’s disease have new evidence that these systems become abnormal a few years before ... last ditch attempt to rescue the brain. , ... Manhasset, NY (Vocus) January 22, 2010 -- Scientists who ...
... , SCOTTSDALE, Ariz. , Jan. 22 ... non-traded, real estate investment trust, announced the execution of a ... medical office portfolio located in Atlanta, Georgia for ... subject to a number of conditions. , The medical office ...
... FORT WASHINGTON, Pa. , Jan. 22 ReSearch Pharmaceutical ... Executive Officer and Steven Bell , Chief Financial Officer, will ... held January 25–27, 2010 in New York City .   ... , at 11:45 am, EST .  Mr. Perlman will also ...
... key, researchers find , FRIDAY, Jan. 22 (HealthDay News) ... of young children,s reading skills, a new study finds. ... influences on learning, but children who come into school ... instruction," lead author Stephen Petrill, a professor of human ...
Cached Medicine News:Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3Health News:ReSearch Pharmaceutical Services, Inc. to Present at Jefferies 2010 Global Healthcare Conference 2Health News:Environment Crucial to Boosting Child's Reading Skills 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
Mylar Plate Sealers 100/Box...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
For use with 96-well plates, catalog # 410150...
Medicine Products: